drugset / Trial / NCT02620007
Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this trial is to assess whether a 12-week treatment with Ciprofloxacin and Rifaximin is superior to placebo to obtain endoscopic remission in adherent-invasive E. coli (AIEC)-colonized patients with ileal Crohn disease (CD), with or without involvement of the caecum or the right colon.
Timeline
- Start
- 2015-12
- Primary completion
- 2021-08
- Completion
- 2022-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ciprofloxacin | Small molecule | 500 mg | Oral |
| Subject | Rifaximin | Other / unclassified | 800 mg | Oral |